Comparing 7-day vs 14-day antifungal treatment for uncomplicated bloodstream yeast infection
Part of Infections clinical trials.
This trial compares two lengths of antifungal treatment for a bloodstream yeast infection that has not spread: 7 days versus the standard 14 days. The goal is to see if a shorter course works just as well with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a yeast infection in your blood that has not spread to other organs.
- You have been on antifungal medicine for less than 5 days.
- You are willing to be randomly assigned to either 7 or 14 days of treatment.
- You do not have a weakened immune system (e.g., from HIV/AIDS, organ or bone marrow transplant, chemotherapy, or very low white blood cell count).
- Your lines (IV or urinary catheters) can be removed, and you do not have any devices that cannot be removed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a shorter course of antifungal medicine to a longer one for people who have candidemia (a yeast infection in the blood). It looks at whether treating for a shorter time is just as safe and effective, which could mean fewer side effects and a quicker recovery.
This trial tests whether a shorter course of the antifungal drug caspofungin (7 days instead of the usual 14) is just as effective for people with uncomplicated candidemia, a bloodstream infection caused by Candida yeast. If you've already had 7 days of caspofungin and your blood is clear of Candida, you might be able to stop treatment sooner.
This Phase 3 trial tests fosmanogepix to treat adults with candidemia (Candida in the bloodstream) and/or invasive candidiasis (a deep Candida infection). It looks at whether the medicine is effective and safe, and whether it helps the infection improve when doctors also manage the infection source.
This trial compares shorter vs longer treatment for children with an uncomplicated yeast (Candida) bloodstream infection once blood cultures are clear. It may help reduce medicine exposure while keeping the infection under control.
This trial studies two types of antifungal medicines (amphotericin B and azoles) to see which works better for people with invasive fungal disease. It aims to help doctors choose the safest and most effective treatment.
This trial tests whether people with a specific type of bloodstream infection caused by gram-negative bacteria can safely take antibiotics for only 5 days instead of longer. It may help by reducing antibiotic exposure if your infection source is controlled quickly.
Hear when a new Candidemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.